KURA
Kura Oncology Inc
NASDAQ · Biotechnology
$7.83
+0.43 (+5.81%)
Income Statement
| FY 2026 | FY 2025 | FY 2024 | FY 2023 | |
|---|---|---|---|---|
| Revenue | 54.42M | 146.41M | 142.51M | 137.24M |
| Net Income | -175,714,475 | 21.31M | 25.50M | 25.40M |
| EPS | — | — | — | — |
| Profit Margin | -322.9% | 14.6% | 17.9% | 18.5% |
| Rev Growth | — | -6.0% | +22.0% | -9.5% |
Balance Sheet
| FY 2026 | FY 2025 | FY 2024 | FY 2023 | |
|---|---|---|---|---|
| Total Debt | 7.66M | 192.12M | 161.82M | 186.45M |
| Total Equity | 333.01M | 502.37M | 476.57M | 529.75M |
| D/E Ratio | 0.02 | 0.38 | 0.34 | 0.35 |
Cash Flow
| FY 2026 | FY 2025 | FY 2024 | FY 2023 | |
|---|---|---|---|---|
| EBITDA | -194,162,189 | 41.90M | 41.44M | 41.75M |
| Free Cash Flow | — | 24.20M | 22.28M | 20.94M |